Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Yufeng Ningxin in Patients With Hypertension
NCT07607275Phase 4
Key facts
- Status
- Recruiting
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Beijing An Zhen Hospital
- Modality
- Small Molecules
- Drugs
- yufeng ningxin
- Conditions
- hypertension (HTN)
01
Overview
Phase 4, randomised, double-blind trial of yufeng ningxin in hypertension (HTN) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Change from baseline in office Systolic Blood Pressure at 8 weeks. Started May 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Control group
Placebo matched to Yufeng Ningxin, 5 tablets 3 times daily
Treatment group
Yufeng Ningxin tablets (0.28 g per tablet), 5 tablets 3 times daily
03
Who it enrols
Adults aged 18-65 with newly diagnosed or untreated essential hypertension (SBP 140-159 mmHg), excluding those with secondary hypertension, severe hepatic/renal disease, poorly controlled diabetes, recent cardiovascular events, or taking interfering medications.
04
Endpoints
Primary
Change from baseline in office Systolic Blood Pressure
Secondary
Change from baseline in office Diastolic Blood Pressure
Change from baseline in mean 24-hour ambulatory SBP/DBP
Change from baseline in mean daytime ambulatory SBP/DBP
Change from baseline in mean nighttime ambulatory SBP/DBP
Headache Impact Test-6
Headache Disability Index
Change from baseline in species-level relative abundance of gut microbiota
Change from baseline in alpha-diversity of gut microbiota
Beyond the preview
Go deeper on NCT07607275.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607275.